Xellia Pharmaceuticals

We’re proud to share that Abhi Misra, CIH, CSP, CEIA has received the Leadership Safety Professional Award - a prestigious recognition given to only a select few safety leaders in India. This recognition highlights his outstanding contributions to workplace safety and his leadership in fostering a culture of well-being and risk prevention. Safety is one of the key pillars of sustainability. As we advance in our Corporate Sustainability Reporting Directive (CSRD) efforts, we continue to integrate safety and responsible business practices into our broader sustainability commitments. At Xellia, we take pride in the expertise and collaboration that drive our success across all regions. This award is a testament to the talent and dedication found throughout our global team. Join us in congratulating Abhi on this distinct achievement! 👏 #Xellia #SafetyLeadership #Sustainability #ExcellenceInAction

Diversity fuels innovation, and every voice matters. At Xellia, we recognize that inclusion isn’t just about one day — it’s about creating a workplace where all talent can thrive. Earlier this year, on International Day of Women and Girls in Science, we highlighted inspiring career advice from female colleagues in STEM. But today, on International Women’s Day, we celebrate the contributions of all women — across every function, every team, and every level of our organization. While there is always work to be done, we remain committed to fostering an environment where diverse talent can succeed. Let’s use this day as a reminder to accelerate action — to challenge barriers, to amplify voices, and to create opportunities for all. 💡 Missed our feature on women in science? Check it out here: https://bit.ly/4bx1gUy #IWD2025 #AccelerateAction #DiversityEquityInclusion #xellia

On International Day of Women and Girls in Science, we celebrate the incredible contributions of women in #STEM, recognizing their vital role and the importance of diversity in driving innovation. At Xellia, we are proud to highlight the journeys of two incredible colleagues - one in Biotechnology and one who grew from Chemistry to Project Management and now Strategic Programs. Despite different paths, their reflections shared a common theme: ✨ Curiosity fuels progress – A passion for continuous learning drives them. 🚀 Challenges are opportunities – They embrace new challenges as stepping stones for growth. 💡 Advice to others? – Don’t be afraid to step out of your comfort zone. That’s where real growth happens. Alexandra Németh-Rieder, Xellia Budapest – “Continuous learning and improvement have been the biggest drives in my career. Working in biotechnology for almost five years, I enjoy widening my knowledge in the field and facing new challenges every day. It is also fascinating that challenging my assumptions can contribute to something that has a great impact!” Anne Mette Nygard, Xellia Oslo – “I am driven by learning new things and constantly look for challenges. Teamwork motivates me; working together to solve an issue and propose a strategy that brings positive results. My career advice? Be curious and don’t be afraid of changes. Not all career development has to be vertical. In a business like ours, having a broad understanding of the industry can be valuable. Push yourself outside your comfort zone – I am sure new opportunities will come your way!” Join us in celebrating all #WomenInScience – their accomplishments and dedication! #InternationalDayofWomenandGirlsinScience #DiversityEquityInclusion #stemcareers #xellia

We’re proud to share that we recently welcomed two exceptional additions to our executive team at Xellia Pharmaceuticals, Alexander Sproedt and Christian Matschke. ✨ Alexander joined us in November as our Chief Strategy & Transformation Officer, bringing with him over a decade of experience from the Life Sciences sector, including Big Biopharma, Generics, Biotech, CDMO and MedTech. Previously a Partner at McKinsey & Company, Alexander is passionate about driving multidisciplinary transformations that enhance performance and foster innovative ways of working. ✨In December, Christian took on the mantle of Chief Operations Officer, contributing an invaluable depth of knowledge built on more than 20 years of leadership experience in pharmaceutical operations. With an expansive track record of driving organizational growth and impact at companies such as Berlin-Chemie, Novartis and Sandoz, Christian’s expertise will be instrumental as we continue to drive excellence and look to the future. Alex and Christian bring a unique combination of experience, strategic vision, and dedication to their respective roles. We are excited about the opportunities ahead as we continue to advance in the pharmaceutical space with their leadership. A few highlights for the new executive members from their introductory weeks include Christian joining the team in one of our production facilities on their morning breakfast meetups for a round of porridge, and Alex’s manufacturing operations tour with our Copenhagen site lead, Michael Uhd – both included in the pictures here. Please join us in giving them a warm welcome! #Xellia #Leadership

Congratulations to Magnus Rasmussen, "Intern of the Year"! We are thrilled to share that Magnus, a former intern and now a valued member of our Quality Control team in Copenhagen, has been named "Intern of the Year" by the Danish Laboratory Association (Dansk Laborant-Forening/HK) Reflecting on the journey, Magnus shared, “It’s been an incredible experience to combine my passion for laboratory work with opportunities to learn and grow at Xellia. I’m excited for what lies ahead!” During his internship, Magnus developed a digital solution to enhance workflows and data integrity – a challenging project that showcased his curiosity and dedication. Now, as a full-time team member, Magnus continues to make a positive impact. Congratulations, Magnus – we are excited to see your future contributions! 📖 Look for Magnus’ inspiring story in the No. 9 issue of LABORANTEN! (Photo by Hanne Loop)

𝗔𝗱𝘃𝗼𝗰𝗮𝗰𝘆 𝗳𝗼𝗿 𝗔𝗰𝘁𝗶𝗼𝗻 Antimicrobial resistance (#AMR) is the "silent epidemic" threatening to reshape global health as we know it. By 2050, AMR is projected to claim more lives annually than cancer, underlining the position as one of the top 10 global health threats. This week, we join the global community in raising awareness, advocating for more robust policies, and highlighting the urgent need for collective action. AMR doesn’t respect borders - it impacts all of us. From researchers developing new treatments, to healthcare professionals saving lives daily, to organizations championing global cooperation, the fight against AMR requires a united front.     At Xellia Pharmaceuticals, we are committed to being part of this mission by ensuring the continuous supply of essential anti-infectives that remain critical in combating resistant infections. This week, we also thank the individuals and institutions leading this battle: policymakers, researchers, healthcare providers, educators, and all our fellow Xellians who tirelessly raise awareness and drive solutions. Join us in turning awareness into action. #AntimicrobialResistance #WAAW2024 #Xellia

Just wrapped up an incredible experience at CPHI Worldwide in Milan. Attending without a booth this year was an interesting experience and aligned perfectly with our mindset—being agile and exploring new ways of engaging. Even so, we held over 120 meetings and hosted a memorable dinner event with key customers and partners. “This was a fantastic opportunity to witness our reputation as a world leader in fermentation-based non-beta-lactam anti-infectives unfold. The event once again highlighted how we are uniquely positioned in the industry, and I couldn’t be more excited about what lies ahead. We are committed to pushing boundaries and staying focused on our mission to provide life-saving treatments”, says Michael Kocher, CEO. Looking forward to keeping these conversations going!

We are pleased to announce that the divestment of our US institutional business to Hikma Pharmaceuticals has been completed, following clearance under applicable US antitrust laws. The transaction includes the Cleveland, Ohio, USA manufacturing site, the in-market institutional, commercial portfolio based in Chicago, Illinois, USA, the drug product R&D pipeline, and the majority of our R&D site in Zagreb, Croatia. The divestment follows a strategic decision to concentrate on the manufacturing and commercializing of fermentation-based anti-infective APIs (Active Pharmaceutical Ingredients) combined with a selected offering of FDFs (Finished Dosage Forms) to the global markets via the B2B sales channel. Michael Kocher, CEO at Xellia Pharmaceuticals, said:  "This is a defining milestone in the transformation journey we embarked on less than a year ago. By focusing on our core strengths, we are positioning Xellia for a robust and prosperous future, enabling us to continue to deliver life-saving products to patients worldwide." Click here to read more - https://bit.ly/4gmixlp

Strategy update! Today we are announcing the divestment of our US institutional business to Hikma Pharmaceuticals, marking a significant milestone in the transformation journey we embarked on almost nine months ago. The transaction, subject to customary closing conditions, will see Hikma acquire our US institutional sales-related operations, including our Cleveland manufacturing site, our commercial portfolio based in Chicago, our R&D pipeline and our R&D site in Zagreb, Croatia. The transaction follows a strategic decision to concentrate on the manufacturing and commercializing of fermentation-based APIs (Active Pharmaceutical Ingredients) for anti-infectives combined with a selected offering of FDFs (Finished Dosage Forms) to the global markets via the B2B sales channel. This strategic pivot will pave the way for a resilient and prosperous future for Xellia, ensuring continued supply of our life-saving products to patients worldwide. Click here to read more - https://bit.ly/4etmhRa

Exciting update! The US Court has lifted the rules imposed on our Cleveland, Ohio facility! Originally set by the FDA and the former owner, the rules were specific to the site's manufacturing operations. Since Xellia took over in 2015, we've been following these rules closely, undergoing regular inspections. And in March 2024, we got a thumbs-up from the FDA, showing we're doing things right. Our Cleveland team has done an amazing job, and we're grateful for their hard work. This is a big win for us and shows our commitment to quality. Let’s keep up the great work! Read the full press release here – https://bit.ly/3UA4Wya #xellia #quality #compliance #xelliacleveland #milestone